Prima BioMed Ltd. is a biotechnology company researching and developing licensed medical biotechnology products in Australia. The company’s lead product is CVac, a cancer vaccine for patients in remission, which has completed two human clinical trials. The company is also developing oral vaccine against human papilloma virus, a virus associated with development of cervical cancer. For more information, visit the company’s website at www.primabiomed.com.au.